Celsion Corporation (CLSN)

[GD]

CEO is not totally honest, the Q rate of $4m cash burn is
for now, once the Gen-1 PII trial enrollment ramps up
fast if the blinded 12 patient data early next year are
very promising, we may see cash burn run up fast too next
year, IMO. By the way, CLSN is selling 1+M shares/Q now,
constantly raising cash which is the reason CLSN is at
$1.7/share, if stree believes CLSN has cash to run up to
early 2021 and not selling shares constantly, CLSN may
be trading at $2.5 to $3 now, IMO. Another biotech I
am watching OMER is in the same place constantly short
of cash, OMER's CEO is playing games with street and think
he can win the funding battle, he is very wrong, no
small biotech short of cash can win with street, soon
or late, CLSN and OMER have pay the dues to the street
for money, the new deal with 100K free shares to Aspire
is the price CLSN is paying Aspire for future $10M funding
to cover second look if needed, IMO.